Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Blood (2023) 142 (Supplement 1): 636.

https://doi.org/10.1182/blood-2023-174750

Published: 2023

Journal Articles

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

Shaun Fleming, MBBS(Hons) FRACP FRCPA, Nik Cummings, Tongted Das, Adam Ivey, BSc, MSc, PhD, Julie McManus, Sharon Avery, MBBS, FRACP, FRCPA, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, David J. Curtis, MBBS,PhD FRACP, FRCPA, Andrew Spencer, MD, Andrew Wei, MBBS, PhD FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 2674.

https://doi.org/10.1182/blood.V130.Suppl_1.2674.2674

Published: 2017

Journal Articles

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

Anish Puliyayil Nair, MD DM, FRACP, Cindy Lee, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Jay Hocking, MD PhDstudent, Sue Morgan, FRACP, FRCPA, MBBS, Daniela Klarica, RN, Jenny Muirhead, Andrew Spencer, Oi Lin Lee, Noemi Horvath, MB, ChB, FRACP, FRCPA

Blood (2016) 128 (22): 4684.

https://doi.org/10.1182/blood.V128.22.4684.4684

Published: 2016

Journal Articles

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Anna Kalff, MBBS, FRACP, FRCPA, Sridurga Mithraprabhu, PhD, Tiffany T. Khong, PhD, Malarmathy Ramachandran, Kate Reed, Hang Quach, MBBS (Hons), FRACP, FRCPA, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Krystal Bergin, Andrew Spencer

Blood (2016) 128 (22): 4515.

https://doi.org/10.1182/blood.V128.22.4515.4515

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Anish Puliyayil Nair, MD DM, Patricia A. Walker, MBBS, FRACP, FRCPA, Anna Kalff, MBBS, FRACP, FRCPA, Krystal Bergin, MBBS, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Jenny Muirhead, Tongted Phomoonna, Daniela Klarica, RN, Andrew Spencer

Blood (2015) 126 (23): 2030.

https://doi.org/10.1182/blood.V126.23.2030.2030

Published: 2015

Journal Articles

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Sumita Ratnasingam, MBBS, Patricia A. Walker, MBBS, Huy Tran, MBBS, Zane Kaplan, MD, James David McFadyen, MD, Huyen Tran, MD, Tse-Chieh Teh, MD, Erica M. Wood, MD, John V. Catalano, MD, Stephen Opat, MBBS, Jake Shortt, MD

Blood (2015) 126 (23): 3457.

https://doi.org/10.1182/blood.V126.23.3457.3457

Published: 2015

Journal Articles

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Anish Puliyayil Nair, MD DM, Shaun Fleming, MBBS (Hons), FRACP, FRCPA, Sharon Avery, MBBS (Hons), FRACP, FRCPA, David J. Curtis, MD, PhD, Sushrut S. Patil, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Jenny Muirhead, Andrew Spencer

Blood (2015) 126 (23): 5543.

https://doi.org/10.1182/blood.V126.23.5543.5543

Published: 2015

Journal Articles

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Tiffany T. Khong, BSc, PhD, Anthony Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Filshie, PhD FRACP, Angela Smiley, Malgorzata Gorniak, Marion Black, Nicole Jenkins, Geoffrey Raines, Andrew Spencer, MBBS FRACP FRCPA MD

Blood (2014) 124 (21): 2103.

https://doi.org/10.1182/blood.V124.21.2103.2103

Published: 2014

Journal Articles

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Anna Kalff, MBBS, FRACP, FRCPA, Nola Kennedy, Patricia A. Walker, MBBS, FRACP, FRCPA, Marion Black, Odette Youdell, Malgorzata Gorniak, Tiffany T. Khong, BSc, PhD, Lona Estifo, Angela Smiley, Anthony P. Schwarer, MD, Andrew W. Roberts, MBBS, PhD, Philip Campbell, MBBS, FRACP, FRCPA, Robin Flishie, Andrew Spencer, MD

Blood (2013) 122 (21): 3223.

https://doi.org/10.1182/blood.V122.21.3223.3223

Published: 2013

Journal Articles

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Philip Campbell, MBBS, FRACP, FRCPA, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Andrew H Wei, MBBS, PhD, Anna Kalff, MBBS, FRACP, FRCPA, Jenny Muirhead, Andrew Spencer, MD

Blood (2013) 122 (21): 2128.

https://doi.org/10.1182/blood.V122.21.2128.2128

Published: 2013

Journal Articles

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Philip Campbell, MBBS, FRACP, FRCPA, Tongted Das, David Kipp, Patricia A. Walker, MBBS, FRACP, FRCPA, Jenny Muirhead, Sharon Avery, MBBS, Sushrut S. Patil, FRACP, FRCPA, David J. Curtis, M.D., Ph.D., Anthony P. Schwarer, MD, Anna Kalff, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2013) 122 (21): 2129.

https://doi.org/10.1182/blood.V122.21.2129.2129

Published: 2013

Journal Articles

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, John Catalano, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Stephen Opat, MD, Nik Cummings, BSc, Andrew Spencer, MD

Blood (2011) 118 (21): 2599.

https://doi.org/10.1182/blood.V118.21.2599.2599

Published: 2011

Journal Articles

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

Chun Yew Fong, MBBS, George Grigoriadis, MBBS, PhD, BSc, Jay Hocking, MBBS, Philip Campbell, MBBS, FRACP, FRCPA, Anthony P. Schwarer, MD, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Hatem H. Salem, MD, FRACP, FRCPA, Andrew Spencer, MD, Andrew H Wei, MBBS, PhD

Blood (2011) 118 (21): 3631.

https://doi.org/10.1182/blood.V118.21.3631.3631

Published: 2011

Journal Articles

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Andrew H Wei, MBBS, PhD, Peter T. Tan, MBBS, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Anthony P. Schwarer, MD, Elchanan H. Januszewicz, MBBS, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Wai Khoon Ho, MBBS FRACP FRCPA, Constantine S. Tam, MBBS, FRACP, FRCPA, Andrew Spencer, MD

Blood (2011) 118 (21): 3625.

https://doi.org/10.1182/blood.V118.21.3625.3625

Published: 2011

Journal Articles

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Peter T. Tan, MBBS, Kate Reed, BSc, Patricia A. Walker, MBBS, FRACP, FRCPA, Sharon Avery, MBBS, Sushrut S. Patil, FRACP FRCPA, Andrew Grigg, MBBS, FRACP, FRCPA, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Othon L Gervasio, DDS, MS, PhD, Ivo J. Winiger, MD, Dirk Hönemann, MD, Andrew H Wei, MBBS, PhD, Andrew Spencer, MD

Blood (2011) 118 (21): 1529.

https://doi.org/10.1182/blood.V118.21.1529.1529

Published: 2011

NARROW

Acalabrutinib ± Obinutuzumab Vs Obinutuzumab + Chlorambucil in Treatment-Naive Chronic Lymphocytic Leukemia: 6-Year Follow-up of Elevate-TN

Post-Allogeneic Stem Cell Transplant Surveillance of CD34+ Sorted Peripheral Blood to Quantify Emergent DNMT3A, IDH and NPM1 clones and Correlation with Clinical Outcome

High Risk Multiple Myeloma: Better Outcomes with Upfront Tandem Autologous- Non-Myelo Ablative Allogeneic Stem Cell Transplantation Compared to Upfront Autologous Stem Cell Transplantation

A 2-Stage Phase II Study of Panobinostat Consolidation in Multiple Myeloma (MM) Patients with < CR Following Single High-Dose Chemotherapy (HDT) Conditioned Autologous Stem Cell Transplantation (ASCT) As Part of First Line Therapy

Autologous Stem Cell Transplantation (ASCT) Followed By Outpatient-Based Non-Myeloblative Allogeneic (NMA) Stem Cell Transplantation (Tandem Auto-Allo) for Biologically Adverse Multiple Myeloma (MM). a Single Centre Experience from Australia

Bortezomib Yields High Response Rates in Antibody-Mediated Autoimmune Hematological Diseases Refractory to Conventional Immunosuppression

Comparison of Cyclophosphamide/Total Body Irradiation (Cy/TBI) and Etoposide/Total Body Irradiation (Etop/TBI) Conditioned Allogeneic Stem Cell Transplant (alloHSCT) for Adult Acute Lymphoblastic Leukaemia (ALL), Data from an Australian Tertiary Care Centre

Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments

Leopard: A Phase II Study Of Post Autologous Stem Cell Transplantation (ASCT) Maintenance Lenalidomide and Prednisolone For Myeloma (MM), Incorporating Minimal Residual Disease (MRD) Assessments

Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma Is Feasible, Efficacious and Associated With Low Transplant-Related Morbidity and Mortality

Incidence and Kinetics Of Full Donor Chimerism and The Impact Of Minimal Residual Disease Status Following Outpatient Non-Myeloablative Allogeneic Stem Cell Transplantation For Myeloma

Azacitidine in Combination with the mTOR Inhibitor Everolimus in Relapsed and Refractory AML

Initial Remission Duration Is the Most Important Predictor of Outcome Following FLAG-Amsacrine Salvage of AML in First Relapse,

A Phase 1b Dose Escalation Safety Analysis of Lenalidomide and Azacitidine Maintenance Therapy for Poor Risk AML,

Determination of the Maximum Tolerated Dose of Panobinostat in Combination with a 5-Day Schedule of Azacitidine in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: Planned Interim Analysis of a Phase Ib/II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only